Nuveen LLC Acquires Shares of 671,411 Replimune Group, Inc. $REPL

Nuveen LLC acquired a new stake in shares of Replimune Group, Inc. (NASDAQ:REPL) in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 671,411 shares of the company’s stock, valued at approximately $6,546,000. Nuveen LLC owned 0.87% of Replimune Group as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also made changes to their positions in the business. Dimensional Fund Advisors LP grew its holdings in Replimune Group by 42.7% during the 4th quarter. Dimensional Fund Advisors LP now owns 778,163 shares of the company’s stock worth $9,425,000 after acquiring an additional 232,822 shares during the last quarter. Nuveen Asset Management LLC increased its position in Replimune Group by 108.9% in the 4th quarter. Nuveen Asset Management LLC now owns 667,634 shares of the company’s stock valued at $8,085,000 after acquiring an additional 347,993 shares in the last quarter. GAMMA Investing LLC increased its position in Replimune Group by 897.2% in the 1st quarter. GAMMA Investing LLC now owns 8,795 shares of the company’s stock valued at $902,000 after acquiring an additional 7,913 shares in the last quarter. Tower Research Capital LLC TRC increased its position in Replimune Group by 696.7% in the 4th quarter. Tower Research Capital LLC TRC now owns 6,772 shares of the company’s stock valued at $82,000 after acquiring an additional 5,922 shares in the last quarter. Finally, ProShare Advisors LLC increased its position in Replimune Group by 33.8% in the 4th quarter. ProShare Advisors LLC now owns 20,788 shares of the company’s stock valued at $252,000 after acquiring an additional 5,247 shares in the last quarter. 92.53% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research firms have weighed in on REPL. Jefferies Financial Group lowered their price objective on shares of Replimune Group from $31.00 to $6.00 and set a “buy” rating for the company in a research report on Tuesday, July 22nd. Cantor Fitzgerald upgraded shares of Replimune Group from a “neutral” rating to an “overweight” rating in a research report on Wednesday, July 30th. Piper Sandler cut shares of Replimune Group from an “overweight” rating to a “neutral” rating and set a $3.00 price objective for the company. in a research report on Tuesday, July 22nd. Wedbush reissued a “neutral” rating and set a $4.00 price objective (down from $19.00) on shares of Replimune Group in a report on Tuesday, July 22nd. Finally, BMO Capital Markets cut Replimune Group from an “outperform” rating to an “underperform” rating and dropped their price objective for the stock from $27.00 to $2.00 in a report on Wednesday, July 23rd. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $7.67.

Insider Activity

In other news, CFO Emily Luisa Hill sold 9,154 shares of the business’s stock in a transaction dated Friday, August 15th. The stock was sold at an average price of $5.37, for a total transaction of $49,156.98. Following the completion of the transaction, the chief financial officer directly owned 134,368 shares in the company, valued at approximately $721,556.16. The trade was a 6.38% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 5.20% of the company’s stock.

Replimune Group Stock Performance

Shares of NASDAQ:REPL opened at $5.67 on Monday. The stock has a market capitalization of $442.60 million, a P/E ratio of -1.75 and a beta of 0.67. Replimune Group, Inc. has a 1-year low of $2.68 and a 1-year high of $17.00. The company has a current ratio of 6.94, a quick ratio of 6.94 and a debt-to-equity ratio of 0.21. The business has a 50-day moving average price of $7.78 and a two-hundred day moving average price of $9.25.

Replimune Group (NASDAQ:REPL) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($0.95) earnings per share for the quarter, missing the consensus estimate of ($0.83) by ($0.12). Equities analysts predict that Replimune Group, Inc. will post -2.97 earnings per share for the current year.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.